Skip to content

BioCryst Pharmaceuticals BCRX Sale of European ORLADEYO business

Sale of European ORLADEYO business at other companies

GE Vernova logo
GE VernovaGEV
-7.7%
GE Vernova logo
GE VernovaGEV
-$48.25M
Cleveland-Cliffs logo
Cleveland-CliffsCLF
$0
The J.M. Smucker Company logo
The J.M. Smucker CompanySJM
0%
Constellation Brands logo
Constellation BrandsSTZ
$1.5M
The J.M. Smucker Company logo
The J.M. Smucker CompanySJM
$0+100%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDisposalOfBusinessPercentage.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's sale of european orladeyo business.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's sale of european ORLADEYO business?
BioCryst Pharmaceuticals (BCRX) reported sale of european ORLADEYO business of 1% in Q4 2025.
What does sale of european ORLADEYO business mean?
Quantifies the percentage point impact on the effective tax rate attributable to the sale of a specific business segment. This metric isolates the tax-related volatility caused by divestitures rather than core operational performance. It helps investors reconcile the reported tax rate with the underlying business operations.